ArticleScience advances2023
Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 89 citations in OpenAlex.
- Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition-Mediated Cuproptosis for Highly Efficient Oncotherapy.Advanced healthcare materials · 2026Article
- Metal-Organic Frameworks (MOFs) for the Delivery of Small-Molecule Therapeutics.Journal of the American Chemical Society · 2026Review
- An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- All-optical strategy for high-speed and subcellular precision drug delivery using Airy beams.Microsystems & nanoengineering · 2026Article
- Immunoregulatory strategies of MOF-based nanodrug delivery systems: Advances in cancer therapy applications and future perspectives.Materials today. Bio · 2026Review
- Adaptive intrathecal nanorobotics in mice and nonhuman primates for navigated CNS therapy.Science advances · 2026Article
- Tutorial: strategies for targeting organelles using nanoparticles.Nature protocols · 2026Review
- Bioinspired, Mitochondria-Targeted Single-Atom Nanozyme Enhances Bone Regeneration by Reprogramming Stem Cell Energy Metabolism.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.Materials today. Bio · 2026Article
- Enhancing the targeting ability of metal-organic frameworks in cancer therapy and diagnosis.Nature reviews. Chemistry · 2026Review
- Nanomaterial-Mediated Targeting of Mitochondrial Metabolism: Strategies and Applications in Cancer Therapy.International journal of nanomedicine · 2026Review
- Nanorobots and Exosomes: Driving the New Frontier for Bladder Tumors through Non-Coding RNAs.Oncology research · 2026Review
- Triple-Targeted DNA Nanozyme Executes Disulfidptosis for Glioma Elimination.Theranostics · 2026Article
- Advancements and challenges of nanorobots in surgical medicine: design, applications, and interdisciplinary integration.Frontiers in bioengineering and biotechnology · 2026Review
- Hybrid-Driven Bacillus Calmette-Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy.ACS applied materials & interfaces · 2025Article
- Jahn-Teller distortion-engineered self-propelled nanorobots for mitochondrial targeting and bioenergetic disruption in tumor therapy.Bioactive materials · 2025Article
- Recent advances in engineering nano/microrobots for tumor treatment.Acta pharmaceutica Sinica. B · 2025Review
- A novel biomimetic nanoplatform amplifies ferroptosis for specific cGAS-STING pathway activation to enhance hepatocellular carcinoma chemo-immunotherapy.Journal of nanobiotechnology · 2025Article
- Biohybrid nanorobots induce lactate isomer conversion to reverse the immune environment and promote tumor therapy.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanorobotic manipulation to access subcellular organelles remains unmet due to the challenge in achieving intracellular controlled propulsion. Intracellular organelles, such as mitochondria, are an emerging therapeutic target with selective targeting and curative efficacy. We report an autonomous nanorobot capable of active mitochondria-targeted drug delivery, prepared by facilely encapsulating mitochondriotropic doxorubicin-triphenylphosphonium (DOX-TPP) inside zeolitic imidazolate framework-67 (ZIF-67) nanoparticles. The catalytic ZIF-67 body can decompose bioavailable hydrogen peroxide overexpressed inside tumor cells to generate effective intracellular mitochondriotropic movement in the presence of TPP cation. This nanorobot-enhanced targeted drug delivery induces mitochondria-mediated apoptosis and mitochondrial dysregulation to improve the in vitro anticancer effect and suppression of cancer cell metastasis, further verified by in vivo evaluations in the subcutaneous tumor model and orthotopic breast tumor model. This nanorobot unlocks a fresh field of nanorobot operation with intracellular organelle access, thereby introducing the next generation of robotic medical devices with organelle-level resolution for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.